Abbott Laboratories (ABT) Interest & Investment Income (2009 - 2026)

Abbott Laboratories has reported Interest & Investment Income for 18 years, with the latest figure at $52.0 million in Q2 2026.

• Quarterly Interest & Investment Income fell 26.76% year-over-year to $52.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $313.0 million (down 6.57% YoY) and the FY2025 annual result came in at $308.0 million, down 49.59% from the prior year.
• Interest & Investment Income fell to $52.0 million in Q2 2026 per ABT's latest filing, from $106.0 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $106.0 million in Q1 2026 and troughed at $14.0 million in Q1 2022.
• A 5-year average of $76.6 million and a median of $82.0 million in 2024 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2022 and 2026: Interest & Investment Income soared 700.0% in 2022, then retreated 26.76% in 2026.
• Over 5 years, Interest & Investment Income stood at $88.0 million in 2022, then advanced by 1.14% to $89.0 million in 2023, then grew by 2.25% to $91.0 million in 2024, then decreased by 14.29% to $78.0 million in 2025, then plunged by 33.33% to $52.0 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $52.0 million, $106.0 million, and $78.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.